Modality
Radioligand
MOA
FcRni
Target
AuroraA
Pathway
Wnt
DLBCLCSUPAH
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ May 2030
Phase 3Current
NCT08445695
2,130 pts·DLBCL
2017-02→TBD·Not yet recruiting
NCT07811972
2,909 pts·DLBCL
2021-02→2029-07·Completed
NCT08627537
2,233 pts·PAH
2025-07→2030-05·Completed
+1 more trial
8,380 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-07-133.3y awayPh3 Readout· DLBCL
2030-05-214.1y awayPh3 Readout· PAH
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Not yet…
P3
Active
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2029-07-13 · 3.3y away
DLBCL
Ph3 Readout
2030-05-21 · 4.1y away
PAH
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08445695 | Phase 3 | DLBCL | Not yet recr... | 2130 | PANSS |
| NCT07811972 | Phase 3 | DLBCL | Completed | 2909 | CR |
| NCT08627537 | Phase 3 | PAH | Completed | 2233 | DOR |
| NCT06016641 | Phase 3 | DLBCL | Active | 1108 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| SND-4562 | Syndax | NDA/BLA | AuroraA |